Tech Company Financing Transactions

Slate Pharmaceuticals Funding Round

Private investors participated in a $2 million funding round for Slate Pharmaceuticals. The financing round was announced on 9/28/2010.

Transaction Overview

Announced On
9/28/2010
Transaction Type
Debt
Amount
$1,990,000
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed. SEC regulatory filing.

Company Information

Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
318 Blackwell Street 240
Durham, NC 27701
USA
Email Address
Overview
Slate Pharmaceuticals, Inc. was founded in 2007 and The company markets an FDA approved subcutaneous implantable testosterone pellet used for the treatment of testosterone deficiency in aging men as well as androgen deficiency caused by other conditions.
Profile
Slate Pharmaceuticals LinkedIn Company Profile
Social Media
Slate Pharmaceuticals Company Twitter Account
Company News
Slate Pharmaceuticals News
Facebook
Slate Pharmaceuticals on Facebook
YouTube
Slate Pharmaceuticals on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Bob Whitehead
  Bob Whitehead LinkedIn Profile  Bob Whitehead Twitter Account  Bob Whitehead News  Bob Whitehead on Facebook


 

 

Browse more venture capital transactions:

Prev: 9/27/2010: Opzi venture capital transaction
Next: 9/28/2010: Phreesia venture capital transaction

 

Share this article

 


Where The Data Comes From

Our team works diligently to document every notable VC transaction. VC investment data records reported here are derived from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary